The pharmaceutical industry is at a pivotal juncture, with the looming threat of patent expirations sending shockwaves through the sector. According to recent market analysis, more than half of the top 15 pharmaceutical companies are gearing up to face significant hurdles as they brace themselves for the impending patent cliff.
As per GlobalData’s report, there is a forecasted decline in the share of global drug sales under patent protection by 2030. The data paints a stark picture – only 4% of global drug sales will enjoy patent protection by then, down from 12% in 2022 and 6% in 2024. This seismic shift is poised to reshape the revenue landscape for major players in Big Pharma.
Historically, losing patent exclusivity has been synonymous with financial turbulence for pharmaceutical giants. Once patents expire, biosimilars and generics flood the market, driving down prices and eroding profits from branded products. This phenomenon exerts immense pricing pressure on companies’ flagship drugs, compelling them to navigate challenging terrain.
In response to this imminent threat, there has been a notable push towards promoting biosimilar and generic drug usage. In a bid to address escalating drug prices, regulatory interventions have come into play. For instance, the Trump administration took decisive action by overhauling pharmaceutical pricing in the United States through an executive order signed in May 2025.
The impact of these changes is palpable – biosimilars and generics can be up to 80% cheaper than their branded counterparts. Take AbbVie’s blockbuster drug Humira (adalimumab), which witnessed a steep revenue decline following the loss of market exclusivity. Once raking in $21.2 billion annually, its revenue is now forecasted to plummet to $2.6 billion by 2030.
Noteworthy contenders like MSD’s Keytruda (pembrolizumab) and Johnson & Johnson’s Darzalex/Faspro are also bracing for intensified competition as their US exclusivity rights expire by 2029. Keytruda alone amassed over $29 billion in sales globally in 2024 but is now set to face headwinds amidst evolving market dynamics.
The repercussions are far-reaching as well – projections indicate that the US drug market stands to lose over $230 billion between this year and 2030 due to patent expirations. Amongst these shifts, Bristol Myers Squibb (BMS) emerges as one of the most heavily impacted players, with key drugs like Eliquis (apixaban) and Opdivo (nivolumab) facing dwindling prospects post-patent expiry.
George El-Helou from GlobalData emphasizes that strategic foresight is crucial during these turbulent times:
“More than half of the top pharma companies will grapple with challenges arising from the approaching patent cliff.”
However, amidst these challenges lie opportunities for innovation and growth.
Eli Lilly stands out as a beacon of hope amid this tumultuous landscape, with forecasts indicating an impressive revenue surge of up to 165% by 2030 driven by promising pipeline assets such as tirzepatide for weight loss and type 2 diabetes management.
Hannah Hans underscores the need for proactive planning:
“It is imperative for pharma companies to adopt an integrated approach encompassing both patent strategies and regulatory considerations early on.”
By focusing on innovative therapies and strategic portfolio realignment efforts, companies can weather this storm effectively.
As pharma firms pivot towards next-generation treatments and novel delivery platforms, collaborations with biotech entities offer fertile ground for growth opportunities. The convergence of expertise holds immense promise for reshaping healthcare landscapes worldwide through groundbreaking therapies tailored to meet unmet medical needs.
In conclusion, navigating through patent cliffs requires agility, foresight, and a steadfast commitment towards innovation-driven strategies that not only mitigate immediate challenges but pave the way for sustained growth in an ever-evolving pharmaceutical terrain.
Leave feedback about this